GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SV-101 overview

SV-101 is under development for non small cell lung cancer (NSCLC) and metastatic breast cancer. It is a fixed-dose combination intratumoral therapy and is being developed based on syncrovax platform technology.

Syncromune overview

Syncromune is a clinical-stage biopharmaceutical business developing a novel cancer treatment that synchronises immune processes and enhances intratumoral immunotherapy to eliminate metastatic solid tumours. The company is headquartered in Fort Lauderdale

For a complete picture of SV-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.